Cann Group Limited

A$0.01As of Sun 8 Nov 2026, 12:00 UTC

ASX:CANHealthcare

Country Australia

PE (Fwd) •••

TSR 9Y CAGR (38.57%)

Div yield —

ROE 157.35%

Drug Manufacturers (Specialty & Generic)

Beta (5Y) 0.05

PE TTM 0.342

TSR TTM (58.33%)

Mkt cap A$8.303M

ROIC (11.29%)

SE Grade™

—

Value

Quality

Moat

Consensus

Reference

$0.0061

21.87%

(86.87%)

Hold 4|11|2|4|0

TTM

FYE 30 Jun AUD

FY2017

FY2018

FY2019

FY2020

FY2021

FY2022

FY2023

FY2024

FY2025

FY2026

FY2027E

Trend

5Y

10Y

Peers

0.190

Revenue$M

0.929

0.953

0.994

1.048

1.096

1.137

1.205

1.253

1.331

1.405

0.210

5.08%

4.95%

23

6.03

Revenue growth%

3.74

1.24

2.19

4.50

3.74

5.42

8.14

7.10

5.02

5.00

5.40

5.42

4.75

95

9.89

Gross margin%

6.18

6.60

5.03

7.25

5.61

5.93

4.90

5.41

8.07

9.13

4.55

5.93

6.05

55

10.26

Operating margin%

10.51

12.22

13.80

11.20

12.59

12.64

10.10

12.37

13.32

12.43

13.68

12.43

12.40

63

27.83

Net margin%

25.88

28.21

28.25

26.46

27.47

27.66

25.54

27.16

24.73

23.31

11.36

25.54

26.81

7

31.51

P/E ratio (avg)x

33.06

33.56

29.51

28.81

28.11

28.98

24.89

25.36

27.60

24.45

13.25

25.36

28.46

67

33.60

EV/EBITx

45.25

44.19

52.18

62.12

66.58

64.36

67.76

69.62

67.41

77.10

13.51

67.76

65.47

92

22.84

FCF yield (avg)%

2.66

2.44

1.09

1.94

0.40

0.40

0.40

0.40

1.13

1.21

11.97

0.40

1.11

58

8.19

FCF margin%

3.78

1.85

2.04

1.84

0.40

0.40

0.40

3.24

4.99

5.77

20.77

3.24

1.94

7

1.010

FCF / Net incomex

0.680

0.671

0.713

0.720

0.807

0.779

0.892

0.961

1.059

1.222

1.413

0.961

0.793

34

20.45

ROIC%

0.40

0.55

0.40

0.40

1.70

3.92

5.27

7.36

7.74

8.65

13.86

7.36

2.81

65

20.12

Return on equity%

16.70

15.67

16.08

14.55

15.32

16.17

15.33

14.19

15.97

14.08

10.03

15.33

15.50

87

4.20

Return on assets%

10.44

9.23

7.75

5.03

4.26

3.82

6.65

4.47

6.43

8.12

13.60

6.43

6.54

19

—

EPS$

—

—

—

—

—

—

—

—

—

—

—

0.14%

2.86%

—

6.30

EPS growth%

14.13

16.61

14.66

16.32

18.47

15.93

13.08

10.39

12.94

12.99

29.18

12.99

14.40

24

—

Bookvalue per sh$

—

—

—

—

—

—

—

—

—

—

—

(4.16%)

(2.60%)

—

—

FCF per share$

—

—

—

—

—

—

—

—

—

—

—

7.18%

7.46%

—

—

Dividend per sh$

—

—

—

—

—

—

—

—

—

—

—

3.12%

3.47%

—

26.17

Div yield (avg)%

29.89

29.78

29.72

32.70

30.48

28.70

29.27

27.01

27.70

27.14

19.36

27.70

29.50

94

17.23

Payout ratio%

13.39

10.94

12.51

10.17

11.12

13.45

11.34

10.31

13.12

11.49

23.80

11.49

11.41

60

1.659

Shares (diluted)B

2.214

2.137

2.539

2.719

3.215

3.086

3.034

3.325

3.775

3.697

1.621

2.84%

5.18%

29

2.84

Buyback yield%

6.49

5.17

3.80

2.76

2.89

4.98

3.68

1.33

0.40

0.70

17.62

1.33

3.29

72

1.740

D/E ratiox

1.485

1.433

1.718

1.743

1.837

1.795

1.934

2.111

2.258

2.488

1.651

2.111

1.816

94

0.311

Enterprise value$M

0.417

0.435

0.481

0.487

0.578

0.595

0.592

0.650

0.639

0.616

0.785

1.26%

3.85%

52

0.387

LT debt$M

1.159

1.103

1.066

1.078

0.943

0.887

0.763

0.655

0.616

0.637

1.184

(7.55%)

(5.87%)

7

Peers (US$5.703M)

Cap (US$)

PE

ECS Botanics Holdings…

5.498M

—

Epsilon Healthcare…

5.345M

148.1x

4.921M

—

Enorama Pharma AB…

6.033M

—

Capital

TTM

5Y

10Y

Leveragex

5.842

0.058

0.054

EBIT/Intx

1.425

0.339

0.330

Own earn%

(463.77)

86.79

107.03

Sh yield%

29.01

28.34

33.45

Owners

Insiders/Inst%

5.72

46.07

Short interest%

5.25

SBC / revenue%

2.41

Record

10Y

Profitable years

10/10

Revenue growth years

10/10

EPS growth years

10/10

Dividend streakyrs

10

Op margin range%

10–14

$1 testx

—

Incr. ROIC%

45

Growth vs revenue

Latest

Trend

10Y CAGR

Rel growth

Revenue

$1.405M

4.95%

1.00×

Cost of revenue

$0.983M

4.95%

1.00×

Operating expenses

$0.286M

4.87%

0.99×